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Abstract
HIV-1 coreceptor tropism assays are required to rule out the presence of CXCR4-tropic (non-R5) viruses prior treatment with
CCR5 antagonists. Phenotypic (e.g., TrofileTM, Monogram Biosciences) and genotypic (e.g., population sequencing linked to
bioinformatic algorithms) assays are the most widely used. Although several next-generation sequencing (NGS) platforms
are available, to date all published deep sequencing HIV-1 tropism studies have used the 454TM Life Sciences/Roche
platform. In this study, HIV-1 co-receptor usage was predicted for twelve patients scheduled to start a maraviroc-based
antiretroviral regimen. The V3 region of the HIV-1 env gene was sequenced using four NGS platforms: 454TM, PacBioH RS
(Pacific Biosciences), IlluminaH, and Ion TorrentTM (Life Technologies). Cross-platform variation was evaluated, including
number of reads, read length and error rates. HIV-1 tropism was inferred using Geno2Pheno, Web PSSM, and the 11/24/25
rule and compared with TrofileTM and virologic response to antiretroviral therapy. Error rates related to insertions/deletions
(indels) and nucleotide substitutions introduced by the four NGS platforms were low compared to the actual HIV-1
sequence variation. Each platform detected all major virus variants within the HIV-1 population with similar frequencies.
Identification of non-R5 viruses was comparable among the four platforms, with minor differences attributable to the
algorithms used to infer HIV-1 tropism. All NGS platforms showed similar concordance with virologic response to the
maraviroc-based regimen (75% to 80% range depending on the algorithm used), compared to Trofile (80%) and population
sequencing (70%). In conclusion, all four NGS platforms were able to detect minority non-R5 variants at comparable levels
suggesting that any NGS-based method can be used to predict HIV-1 coreceptor usage.
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Introduction
The discovery that human immunodeficiency virus type 1
(HIV-1) requires a co-receptor to enter target cells, mainly the
chemokine receptors CCR5 or CXCR4 [1,2], was not only crucial
to better understand HIV-1 transmission and pathogenesis but
opened the door for the designing of novel antiretroviral drugs
targeting host cell entry. Multiple strategies to block the replication
of CCR5- or CXCR4-tropic (R5 or X4, respectively) viruses have
been studied [3], leading to the approval for clinical use of the first
CCR5-receptor antagonist (maraviroc, Selzentry/Celsentri, Pfizer,
NY) in 2007 [4]. Like other co-receptor antagonists in develop-
ment, maraviroc’s activity is very specific, showing no direct
activity against viruses able to use CXCR4 to enter the target cell
[5,6]. Thus, an HIV-1 tropism test should be performed prior to
initiation of maraviroc-containing regimens to rule out the
presence of detectable non-CCR5-tropic (non-R5) virus [7,8,9].
Several phenotypic and genotypic assays have been developed
to assess HIV-1 co-receptor usage or tropism [7]. Most phenotypic
assays involve the generation of patient-derived env-recombinant
viruses to determine their ability to infect reporter cell lines
expressing HIV-1 receptors and co-receptors [10,11,12,13]. The
new version of TrofileTM (Monogram Biosciences, South San
Francisco, CA) [11], i.e., the Enhanced Sensitivity Trofile Assay
(ESTA) [14] is currently the most widely used HIV-1 coreceptor
tropism assay. Nonetheless, phenotypic assays share a few practical
limitations such as high cost and long turnaround time, which
restrict their use and consequentially hinder access to future CCR5
antagonists/agonists.
Genotypic tests are a faster, less expensive alternative to
inferring HIV-1 coreceptor tropism from env sequences [7,8].
Considerable effort has been made to develop genotypic assays
able to predict HIV-1 co-receptor usage based on just the V3
region of the env gene [7,9,15], which seems to be the principal
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determinant of HIV-1 tropism [16,17]. However, genotypic tests
based on bulk capillary electrophoresis (Sanger) sequencing of a
population of V3 sequences lack the sensitivity to detect minority
variants present below 20% of the viral population [18,19,20,21].
For that reason, several studies have evaluated the use of next-
generation (NGS) or deep sequencing to detect minority non-R5
HIV-1 variants [22,23,24,25,26,27,28] or low frequency drug-
resistant variants that could lead to treatment failure
[29,30,31,32,33]. Prediction of HIV-1 coreceptor usage by deep
sequencing is highly concordant with phenotypic assays (82% to
87%) [25,28,34], has improved sensitivity for detecting non-R5
variants over population sequencing [22,25,27,35,36], and
predicts the success of maraviroc-based antiretroviral regimens
[25,28].
To date all published HIV-1 deep sequencing studies have used
the 454TM Life Sciences platform (454 Life Sciences/Roche,
Branford, CT); some of which were focused on HIV-1 tropism
prediction [22,23,24,25,27,28,34,35,37,38]. The advent of novel
NGS technologies offering different chemistries, simplified sample
preparation, faster turnaround times, and reduced cost per bp
sequenced prompted us to compare the ability of four NGS
platforms, i.e., 454TM Life Sciences/Roche, IlluminaH (Illumina,
Inc. San Diego, CA), PacBioH RS (Pacific Biosciences, Menlo Park,
CA), and Ion TorrentTM (Ion Torrent/Life Technologies, South
San Francisco, CA) to determine HIV-1 coreceptor tropism.
Materials and Methods
Clinical samples
Twelve RNA specimens, derived from plasma samples collected
from HIV-infected individuals prior to enrollment in the (i)
maraviroc expanded access program (EAP) at multiple centers in
Europe or (ii) ALLEGRO trial, a multicenter study to assess the
Figure 1. Schema summarizing the strategy followed in this study to compare the use of the four next-generation sequencing
platforms (454TM, IlluminaH, PacBioH, and Ion TorrentTM) to determine HIV-1 coreceptor tropism (see text for full details).
doi:10.1371/journal.pone.0049602.g001
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prevalence of R5 HIV-1 variants in Spain [39], were obtained
from the Hospital Carlos III (Madrid, Spain) [21]. Phenotypic
HIV-1 coreceptor tropism was determined at baseline using the
original version of the TrofileTM assay (Monogram Biosciences),
which had a reported non-R5 variant detection limit of 5 to 10%
[11]. Written informed consent was obtained from the patients
before participation in the study as previously described [21,39].
RT-PCR amplification
Viral RNA was reverse-transcribed using AccuScript High
Fidelity Reverse Transcriptase (Stratagene Agilent; Santa Clara,
CA) and the corresponding antisense external primer in 20-ml
reaction mixture containing 1 mM dNTPs, 10 mM DTT and 10
units of RNase inhibitor. Viral cDNA was then PCR amplified
using a series of external and nested primers with defined cycling
conditions. Using the same external (first-round) PCR reactions
that covered the entire HIV-1 envelope (env) gene (2,830 nt), two
different PCR fragments were amplified due to intrinsic require-
ments of each NGS platform (Fig. 1). These twelve samples are
part of a larger cohort analyzed in a separate study (Weber and
Quinones-Mateu, submitted for publication). In that study 105
patient-derived 337 bp amplicons corresponding to a short region
around the HIV-1 V3 loop were analyzed with the 454TM system.
Here, we were able to sequence the same amplicons using the
PacBioH RS platform; however, the IlluminaH and Ion TorrentTM
systems used in this study are better suited to sequence longer
DNA regions, shearing them into small fragments (150 to 200 bp).
Processing and sequencing the small 337 bp PCR products may
have been difficult with these two platforms. Thus, 337-nucleotide
(nt) fragments encompassing the V3 region were generated in
single nested (second-round) PCR reactions. These small ampli-
cons were sequenced using 454TM and PacBioH RS sequencing
systems. A larger fragment corresponding to the env gene was
amplified as a 2,302 nt fragment, that is, all the surface
glycoprotein (gp120) and most of the transmembrane glycoprotein
(gp41), missing only 321 nt of the gp41 cytoplasmic domain.
These amplicons were sequenced using IlluminaH and Ion
TorrentTM platforms. External PCR reactions were carried out
in a 50-ml mixture containing 0.2 mM dNTPs, 3 mM MgCl2 and
2.5 units of Pfu Turbo DNA Polymerase (Stratagene). Nested PCR
reactions for population sequencing analysis were carried out in
50-ml mixture containing 0.2 mM dNTPs, 0.3 units of Pfu Turbo
DNA Polymerase and 1.9 units of Taq Polymerase (Denville
Scientific; Metuchen, NJ), then purified with the QIAquick PCR
Purification kit (Qiagen) and quantified with Quant-iT PicoGreen
dsDNA kit (Invitrogen). Nested PCR reactions for deep sequenc-
ing analysis were customized for each NGS system as described
below.
Population (standard Sanger) sequence analysis
PCR products corresponding to the gp120/gp41-coding regions
of HIV-1 were purified with the QIAquick PCR Purification kit
(Qiagen) and the V3 region sequenced (population or global
sequence) using AP Biotech DYEnamic ET Terminator cycle with
Thermosequenase II (Davis Sequencing LCC, Davis, CA) (Fig. 1).
Nucleotide sequences were analyzed using DNASTAR Lasergene
Software Suite v.7.1.0 (Madison, WI).
Deep sequencing of the V3 region of env
Second-round PCR amplification and deep sequencing analysis
was customized for each NGS platform as follows:
– 454/Roche: A 337-nt fragment encompassing the V3 region was
generated by nested PCR from an external PCR product
containing the entire env gene (2,830 nt) as described above.
Single nested PCR reactions were carried out with Phusion
High-Fidelity DNA Polymerase (New England Biolabs, Ips-
wich, MA) in a 50 ml-reaction mixture containing 0.2 mM
dNTPs, 2.5 mM MgCl2, and 0.2 mM of both the antisense and
barcoded sense primers. PCR products were purified with the
QIAquick PCR Purification kit (Qiagen) and quantified with
Quant-iT PicoGreen dsDNA kit (Invitrogen). Pooled PCR
Table 1. Clinical and virological parameters of HIV-infected individuals.
Sample Studya CD4
+ T-cell count (cells/ml) at Plasma Viral Load (copies/ml) at
Virologic response
at HIV-1 tropism
Baseline Week 12 Baseline Week 12 week 12b at baselinec
10–65 EAP 166 18 1,500,000 437,000 No R5
10–69 EAP 230 388 9,476 49 Yes R5
10–73 EAP 268 225 15,778 39,995 No R5
10–75 EAP 211 n.d. 27,200 n.d. n.a. R5
10–80 EAP n.d. n.d. n.d. n.d. End of Study D/M
10–91 EAP 28 239 168,000 39 Yes R5
10–105 Allegro n.d. n.d. n.d. n.d. n.a. n.d.
10–133 EAP 30 250 56,445 96 Yes R5
10–137 EAP 353 420 n.d. 49 Yes R5
10–172 EAP n.d. n.d. n.d. n.d. End of Study D/M
10–176 EAP n.d. n.d. n.d. n.d. End of Study D/M
10–180 EAP 204 338 8,800 180 Yes R5
aEAP, Expanded Access Program for the use of maraviroc at multiple centers; Allegro, multicenter study to assess the prevalence of R5 HIV-1 variants in Spain [39].
bVirologic response at week 12 following a maraviroc-based antiretroviral regimen, defined as a decrease in plasma viral load below 400 copies/ml. End of study, HIV-
infected individuals did not enter the study following the detection of non-R5 viruses at baseline (see below); n.a., not available.
CHIV-1 coreceptor tropism was determined at baseline using a phenotypic test, i.e., the original TrofileTM assay (Monogram Biosciences) [11]. R5, CCR5-tropic virus; D/M,
dual mixed, that is a combination of CCR5- and CXCR4-tropic viruses; n.d., not determined.
doi:10.1371/journal.pone.0049602.t001
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products were clonally amplified on capture beads in water-oil-
emulsion micro-reactors. A total of 500,000 HIV-1 env
enriched-DNA beads were deposited in the wells of a 454
GS FLX instrument (454 Life Sciences/Roche) and pyrose-
quenced in forward direction using 200 cycles in a ten-hour
sequencing run.
– Illumina: A 2,302 nt fragment of the env gene was amplified
from an external PCR product as described above for the
population sequencing, then purified (QIAquick PCR Purifi-
cation, Qiagen) and quantified (Quant-iT PicoGreen dsDNA,
Invitrogen). Paired-end DNA libraries were prepared using
Nextera DNA sample prep kit (Epicentre Biotechnologies,
Madison, WI) according to manufacturer’s protocol. Briefly,
50 ng of PCR product were subjected to tagmentation with
high-molecular-weight buffer and Nextera enzyme mix at 55uC
for 5 minutes followed by limited nine-cycle PCR using half of
the purified tagmentation reaction with Nextera PCR mix.
Amplicons were then purified using Zymo Clean-up kit (Zymo
Research, Irvine, CA), shipped to Illumina, Inc. (San Diego,
CA) and used as input for bPCR and cluster preparation
according to standard Illumina protocol. Amplicons were
sequenced on the Illumina Genome Analyzer IIx (GAIIx) using
version 5 chemistry.
– Pacific Biosciences: A 337 nt fragment encompassing the V3
region was generated by nested PCR from a external PCR
product containing the entire env gene (2,830 nt) as described
above for 454/Roche. Unpurified PCR products were shipped
to Pacific Biosciences (Menlo Park, CA) where, after visuali-
zation by electrophoresis through 1.2% agarose gel (Lonza
Flashgel), the PCR reactions were purified (QIAquick PCR
Purification, Qiagen) according to the manufacturer’s instruc-
tions. Each sample was eluted into 30 ml of EB buffer (10 mM
Tris pH 8.0), re-visualized by electrophoresis, then quantified
using UV spectrophotometry (NanoDrop, Thermo Scientific,
Wilmington, DE). A total of 2 mg for each sample was used as
input into library preparation using standard Pacific Biosci-
ences version C1 chemistry, with the following modifications:
templates were annealed at 40 nM DNA concentration,
80 nM primer concentration, and Polymerase:Template bind-
ing reactions were at 18 nM using ECR2 enzyme (Pacific
Biosciences). The samples were sequenced on the PacBio RS
running version 1.2.1 software with the standard 2645 minute
collection protocol, and one SMRTCell was used for each
sample. Circular consensus sequencing (CCS) reads were
generated from zero mode waveguides (ZMW) containing
three or more sequencing passes across the template.
Ion Torrent. A 2,302 nt fragment of the env gene was
amplified from an external PCR product, then purified (QIAquick
PCR Purification, Qiagen) and quantified (Quant-iT PicoGreen
dsDNA, Invitrogen) as described above for Illumina. The Ion
XpressTM Fragment Library Kit (Life Technologies, Carlsbad CA)
was used to construct a library for shotgun sequencing on the Ion
Personal Genome Machine (PGM, Ion Torrent/Life Technolo-
gies). Briefly, amplicon DNA was randomly fragmented using the
Ion ShearTM Plus Reagent (Life Technologies). The P1 adapter
(59-CCA CTA CGC CTC CGC TTT CCT CTC TAT GGG
CAG TCG GTG AT; 59-ATC ACC GAC TGC CCA TAG AGA
GGA AAG CGG AGG CGT AGT GG*T*T) or one of 12 A_BC
adapters were then ligated to the repaired fragment ends.
Following ligation and size selection (i.e., 150+/220 nucleotides;
Pippin PrepTM, Life Technologies) the library was PCR amplified
using forward (59-CCA TCT CAT CCC TGC GTG TC) and
reverse (59-CCA CTA CGC CTC CGC TTT CCT CTC TAT
G) primers. The quality and quantity of each of the 12 libraries
was assessed with the 2100 Bioanalyzer (DNA High Sensitivity
Chip, Agilent Technologies, Sunnyvale CA). Templates were then
prepared and enriched for sequencing on the Ion Sphere
ParticlesTM (ISPs) using the Ion XpressTM Template Kit (Life
Technologies) prior to sequencing on the Ion PGM with the Ion
Sequencing Kit (Life Technologies). Fifteen million templated ISPs
were primed with the Ion Sequencing primer (59-CCA TCT CAT
Figure 2. Comparison of data processing across NGS platforms. Number of sequencing errors, substitutions, deletions, and insertions (per
read) for the NGS platforms: 454TM, IlluminaH, PacBioH, and Ion TorrentTM. The mean and interquartile range (IQR) are indicated for each sample.
Whiskers indicate 1.5 times the IQR as is the default value in the R-statistical package [75].
doi:10.1371/journal.pone.0049602.g002
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CCC TGC GTG TCT CCG AC) and then mixed with the Ion
Sequencing Polymerase. The primer-activated polymerase-bound
ISPs were loaded into the Ion 314TM Chip (Life Technologies) and
subjected to 65 cycles of sequencing with the standard nucleotide
flow order. Signal processing and base calling was performed with
Torrent Analysis Suite version 1.5.
Finally, it is important to note that the 454TM sequencing was
performed in the laboratory of Dr. Hendrik Poinar (McMaster
University, Hamilton, Canada), while for IlluminaH, PacBioH, and
Ion TorrentTM the PCR products were sent for sequencing at the
respective company. V3 nucleotide sequences obtained by deep
sequencing using any of the NGS platforms (as described below)
have been submitted to the Los Alamos National Laboratory HIV-
DB Next Generation Sequence Archive (http://www.hiv.lanl.
gov/content/sequence/HIV/NextGenArchive/Archer2012).
Read mapping, variant sensitivity and phylogenetic
inference
To minimize the amount of data loss due to high sequence
variability and to allow for interpatient indel variation across the
V3 region, sample-specific reference sequences were constructed
as previously described [24]. First, sequences corresponding to the
HIV genomic region spanning positions 6,900 to 7,400 on the
HXB2 reference strain (accession no: K03455) were extracted,
followed by replacement with the V3 population sequence derived
from each sample. For each sample, reads derived from the four
NGS platforms were then independently mapped to the respective
sample-specific reference sequence (Fig. 1) and all indel and
substitution information in relation to the reference sequenced
stored as described [40]. For each dataset, reads spanning the V3
region (coordinates 210 to 315 within the reference templates)
were extracted, truncated and translated for genotyping. Within
each dataset only one representative of any identical variant was
maintained, but the overall frequency stored. Finally, all variants
with a frequency .5 within the population, calculated by each
platform, were combined and clustered using a neighbor-joining
algorithm implemented within Segminator II [40].
HIV-1 coreceptor tropism determination
HIV-1 co-receptor tropism was predicted from population and
extracted V3 read data as described above using several
bioinformatics tools (Fig. 1). In the case of global sequences,
nucleotide mixtures were considered when the second highest peak
in the electropherogram was above 25%, and then these
nucleotide mixtures were translated into all possible permutations.
The algorithms used to infer HIV-1 tropism from V3 amino acid
sequences were: (i) Geno2Pheno [41], with false positive rates
(FPR, i.e., predicted frequency of classifying an R5 sequence as
non-R5 virus) based on optimized cutoffs for determining HIV-1
coreceptor usage (3.5%) as previously described [25,28,42] or the
recommendation from the European Consensus Group on clinical
management of HIV-1 tropism testing (10%) as described in the
Geno2Pheno website (http://coreceptor.bioinf.mpi-inf.mpg.de/
index.php), (ii) Web PSSM using the subtype B x4r5 matrix
[43], and (iii) the 11/24/25 charge rule [44,45] implemented
within our analysis pipeline. Finally, plasma samples were
classified as containing non-R5 viruses if at least 2% of the
individual sequences, as determined by deep sequencing, were
predicted to be non-R5 [25,28].
Statistical analyses
Descriptive results are expressed as median values, interquartile
ranges, and standard deviations. Pearson correlation coefficient
was used to determine the strength of association between
categorical variables. All differences with a P value of ,0.05 were
considered statistically significant. The kappa coefficient, which
assesses a chance-adjusted measure of the agreement between any
number of categories, was calculated using ComKappa2 v.2.0.4
[46] to quantify the concordance among the different the HIV-1
tropism determinations and the patient’s virologic response at
week 12. Values of kappa can range from 21.0 to 1.0, with 21.0
indicating perfect disagreement below chance, 0.0 indicating
agreement equal to chance, and 1.0 indicating perfect agreement
above chance. A rule of thumb is that kappa values ,0.40 indicate
poor agreement,$.40,0.75 indicate good agreement, and$0.75
,1.0 indicate excellent agreement. All statistical analyses were
performed using GraphPad Prism v.5.01 (GraphPad Software, La
Jolla, CA) unless otherwise specified.
Results
Clinical samples
Twelve representative specimens were selected from 167
patients analyzed in a study comparing phenotypic and genotypic
HIV-1 coreceptor tropism assays [13] based on the level of
concordance among the different tests. Eleven samples corre-
sponded to patients participating in the maraviroc EAP, with three
failing to enter the study following the detection of non-R5 (D/M)
variants at baseline and five out of the remaining eight patients
responding to the maraviroc-based regimen at week 12 (Table 1).
Population sequencing was performed not only to infer HIV-1
tropism but also to verify sample identity, showing a 99.9%
homology with the V3 nucleotide sequences published for these
specimens [21] (data not shown).
Data processing and NGS platform error rates
For each platform, the number of reads containing successfully
mapped and complete V3 sequences, as well as those that were
subsequently translated, were calculated. All insertions, deletions,
and substitutions relative to the sample-specific reference sequenc-
es were tabulated during read mapping, and prior to any filtering
based on correctly translating entire V3 sequences (Table 2). In
general, all platforms showed low substitution (1.8, 1.7, 1.3, and
1.7 mean #/read), deletion (0.2, 0.01, 0.4, and 0.5 mean #/read),
and insertion (2.1, 1.7, 1.9, and 2.4 mean #/read) rates across all
samples for 454TM, IlluminaH, PacBioH, and Ion TorrentTM,
respectively (Fig. 2 and Table 2). As expected, there was
interpatient variability; for example, sample 10–172 showed
slightly higher substitution (5.1, 5.1, 2.5, and 5.1 mean #/read)
and insertion (4.5, 4.0, 2.9, and 5.5 mean #/read) rates across all
platforms compared with the other samples. Nevertheless, the
overall low rates of indels and substitutions resulted in a high
number of successfully translated V3 sequences from the original
V3 spanning reads, suggesting that each one of the NGS platforms
could be used for genotyping of complex HIV-1 populations.
Figure 3. Comparison of the frequency of variants across NGS platforms. The heights of the bars represent the combined frequency of V3
variants detected by the NGS platforms 454TM, IlluminaH, PacBioH, and Ion TorrentTM prior to filtering. The colors within each bar denote the
proportional contribution made by each platform after normalization based on coverage. Insets show low frequency variants up to a maximum of 20
unique sequences.
doi:10.1371/journal.pone.0049602.g003
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Figure 4. Comparison of the clustering of variants across platforms. The ten most common nucleotide V3 sequences from samples 10–65,
10–69, and 10–73 -obtained with each of the four NGS platforms (454TM, IlluminaH, PacBioH, and Ion TorrentTM)- were aligned against the respective
population (sanger) sequence from the respective patient using Clustal X 2.0 [76]. For each patient, every unique variant is identified by the NGS
platform used and the number of sequences (frequency) obtained, e.g., 454#1290. For each position only those nucleotides that differ from the
NextGen Sequencing and HIV-1 Tropism
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HIV-1 population diversity
All major virus variants were detected by each platform with
similar frequency, with the exception of sample 10–137 where Ion
Torrent detected a different dominant variant than the other three
platforms or in sample 10–172 where an insertion of three
nucleotides was observed in most variants sequenced with 454,
Illumina, and PacBio but not with Ion Torrent (Figs. 3, 4, and 5).
All the amplicons, either the 337-nt fragments encompassing the
V3 region or the 2,302 nt fragments covering most of the env gene,
were obtained from the same external PCR products; however,
the amplicons sequenced by Ion Torrent were generated seven
months later than the products analyzed by the other NGS
platforms. Thus, it is possible that in some cases (such as with
sample 10–137) a different majority variant within the quasispecies
population may have been selected during PCR amplification.
Moreover, in some cases and at lower frequencies, unique variants
were platform-dependent, probably related to platform-dependent
error rates and/or stochastic PCR errors (Fig. 3). Nevertheless,
and in general, all platforms were able to identify the same major
variants within the population and similar proportion of low
frequency variants (i.e., at a frequency ,0.5%) (Fig. 3, inserts). For
example, mixtures of at least two predominant populations were
accurately identified by all four NGS platforms in samples 10–80,
10–133, and 10–180 (Figs. 3, 4, 5, and 6). Phylogenetic trees
constructed by combining V3 sequences obtained with each
platform confirmed these findings (Figs. 4, 5, 6, and 7).
HIV-1 tropism determination by deep sequencing
relative to TrofileTM and population-based sequencing
The main goal of this study was to evaluate the ability of the
four NGS platforms to determine HIV-1 coreceptor tropism. For
that, the ten samples with known virologic response at week 12
(Table 1) were selected to compare the results from phenotypic
and genotypic (population and deep sequencing) HIV-1 tropism
assays, the latest using four different algorithms to predict HIV-1
coreceptor usage. Minority non-R5 variants were detected at
comparable levels with a few exceptions mainly linked to the
algorithm used to infer HIV-1 tropism rather than the NGS
platform. For example, PacBioH (samples 10–91, 10–176, and 10–
180; 11/24/125 rule) and Ion TorrentTM (samples 10–180 and
10–69; 11/24/25 rule and Geno2Pheno, respectively) detected a
higher frequency of non-R5 variants than the other NGS systems
(Fig. 8).
Interestingly, only the two samples carrying almost exclusively
X4 viruses (10–80 and 10–172) were classified as non-R5 by all
four algorithms (i.e., 11/24/25, Geno2Pheno 3.5% FPR,
Geno2Pheno 10% FPR, and PSSM) based on a frequency of
non-R5 variants $2% within the viral population. The most
stringent Geno2Pheno 3.5% FPR failed to call one sample
determined as D/M by Trofile (10–176) and specimens from two
patients with virologic failure at week 12 (10–65 and 10–73). Not
surprisingly, Geno2Pheno 10% FPR was able to call two of these
samples as non-R5 (10–65 and 10–176) but also classified a patient
with virologic success (10–180) as carrying non-R5 variants (Fig. 8).
Finally, despite the limited sample number, prediction of HIV-1
coreceptor usage by all four NGS platforms showed similar
concordance with the virologic response at week 12, ranging from
75% to 80% (kappa coefficients of 0.5 to 0.6, P,0.001) depending
on the algorithm used, compared to Trofile (80%, kappa
coefficient of 0.6) and population sequencing (mean 70%, kappa
coefficient 0.4).
Discussion
The use of CCR5 antagonists to block HIV-1 replication has
accelerated the development of HIV-1 coreceptor tropism assays
[7,8,9] and stressed the need for novel, sensitive, and more
affordable tests to increase treatment with this drug class. Although
Trofile is the most commonly used phenotypic assay for HIV-1
coreceptor tropism, less sensitive genotypic tests based on HIV-1
population (Sanger) sequencing are frequently used in Europe,
leading to the rapid adoption of deep sequencing technologies in
genotypic HIV-1 coreceptor tropism protocols
[22,23,24,25,27,28,34,35,36,47]. Based on the need for these
NGS-based genotypic assays, we have compared the ability of four
NGS platforms (454TM, IlluminaH, PacBioH, and Ion TorrentTM)
to detect minority variants, and to infer the presence of non-R5
viruses within the HIV-1 population.
Next generation sequencing has been used in a multitude of
biological fields, from the sequencing of whole genomes of
animals, plants, and microbes, to targeted studies on polymor-
phisms related to various genetic disorders and cancer, most of
them based on IlluminaH [48,49,50,51] and 454TM [52,53,54]
platforms and more recently using PacBioH [55,56,57] and Ion
TorrentTM [58,59,60] systems. To date all published HIV-related
studies have used the 454TM platform, due in part to being one of
the first NGS systems to provide longer read lengths [53,61]. As
expected each deep sequencing platform differs in terms of the
chemistry, read length, yield, error rate, turn-around time, and
overall cost [62,63]. Here, we sequenced the HIV-1 V3 region
from the same RNA aliquots obtained from 12 patients and
showed that all four NGS platforms had similar substitution and
insertion rates (ranging from 1.3 to 1.8 and 1.7 to 2.4 mean #/
read, respectively), while IlluminaH had the fewest deletions per
read (0.01 versus a range of 0.2–0.5 mean #/read for the other
three platforms). This is consistent with the reduced number of
indels reported for IlluminaH when compared with 454TM during
the genome sequencing of Gallus gallus [64] or influenza virus [40]
and the sequencing of a strain of Escherichia coli using 454TM and
Ion TorrentTM [65].
We observed differences in the number of V3 sequences and
mean read length among the NGS platforms, which were due to
both the size of the PCR product selected for sequencing and
intrinsic characteristics of the sequencing method. Short amplicons
(337 nt) containing the V3 region were sequenced using 454TM
and PacBioH; however, library preparation and shotgun sequenc-
ing was performed on the entire PCR-amplified env gene (2,302 nt)
using IlluminaH and Ion TorrentTM. In addition, the 454TM
sequencing was performed in-house using barcoded sequencing
primers while for IlluminaH, PacBioH, and Ion TorrentTM the
amplicons were sent for sequencing at the respective company.
Despite these differences, all NGS platforms were able to detect
the same higher frequency variants but showed slightly variations
population sequence are depicted. Dashes indicated the same nucleotide as the population sequence while gaps introduced to maintain the
alignment are indicated by dots. Relative clustering of the data from the NGS platforms was inferred by neighbor-joining, phylogenetic analyses
determined using MEGA 5.05 [77] and displayed in a circle with topology only to facilitate their interpretation. Bootstrap resampling (1,000 data sets)
of the multiple alignments tested the statistical robustness of the trees, with percentage values above 60% indicated by an asterisk. The size of the
circles in the phylogenetic trees correlates with the frequency of the unique sequence determined by each NGS platform (color) in the logarithmic
scale. The black box denotes the population (sanger) sequence for each sample.
doi:10.1371/journal.pone.0049602.g004
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Figure 5. Comparison of the clustering of variants across platforms. The ten most common nucleotide V3 sequences from samples 10–75,
10–80, and 10–91 -obtained with each of the four NGS platforms (454TM, IlluminaH, PacBioH, and Ion TorrentTM)- were aligned against the respective
population (sanger) sequence and analyzed as described in the Figure 4 legend.
doi:10.1371/journal.pone.0049602.g005
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Figure 6. Comparison of the clustering of variants across platforms. The ten most common nucleotide V3 sequences from samples 10–105,
10–133, and 10–137 -obtained with each of the four NGS platforms (454TM, IlluminaH, PacBioH, and Ion TorrentTM)- were aligned against the
respective population (sanger) sequence and analyzed as described in the Figure 4 legend.
doi:10.1371/journal.pone.0049602.g006
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Figure 7. Comparison of the clustering of variants across platforms. The ten most common nucleotide V3 sequences from samples 10–172,
10–176, and 10–180 -obtained with each of the four NGS platforms (454TM, IlluminaH, PacBioH, and Ion TorrentTM)- were aligned against the
respective population (sanger) sequence and analyzed as described in the Figure 4 legend.
doi:10.1371/journal.pone.0049602.g007
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in the detection of low frequency variants (,0.5%), which had
limited implications for HIV-1 tropism. It is important to note that
based on HIV-1 clonal sequencing the error rate for in-house
454TM sequencing assays has been calculated to be between 0.1%
and 0.5% [23,34,66,67]; therefore, we only used variants present
at $1% of the viral population for diversity and HIV-1 tropism
analyses.
Multiple studies have compared the efficacy of phenotypic and
genotypic HIV-1 tropism assays to detect non-R5 variants
[68,69,70,71,72]. In general, population-based sequencing tests
are less sensitive and less specific than phenotypic assays [7,73],
although a few studies have shown significant concordance and
predictive values [28,72,74]. More sensitive deep sequencing
methods for HIV-1 coreceptor tropism assays resulted in the
detection of minor variants, which correlated well with both
phenotypic assays [13,25,28,34] and virological response to
maraviroc [25,28]. Here we have shown that all four NGS
platforms provide equal and sensitive detection of minority non-
R5 viruses in 12 patients, with minor differences depending on the
bioinformatic algorithm used to infer HIV-1 tropism. However, it
is important to stress that maraviroc was combined with at least
two other antiretroviral drugs and increased viral loads could be
due to several factors including poor or selective drug adherence
and resistance to other drugs while maintaining partial maraviroc
suppression. Nevertheless, all four NGS platforms showed similar
concordance with virologic response at week 12 (ranging from
75% to 80% depending on the algorithm used), compared to
Trofile (80%) and population sequencing (70%). Despite the
limited number of samples, these results are comparable to
previous studies where deep sequencing had a good concordance
with phenotypic HIV1- tropism tests (82% to 87%) [25,28,34] and
matched TrofileTM in predicting the success of maraviroc-based
antiretroviral regimens [28].
In conclusion, this is the first study comparing the ability of the
four current leaders in deep sequencing (454TM, IlluminaH,
PacBioH, and Ion TorrentTM) to detect minority variants, and to
infer the presence of non-R5 viruses, within the HIV-1 population.
Despite minor differences in error rates and profiles (types of
errors), all four NGS platforms successfully detected the same
unique viral variants present at high frequencies, which are the
sequences relevant for the clinical determination of HIV-1
coreceptor tropism. Further studies with larger number of patients
and the latest chemistry and software for each NGS system will be
needed to corroborate our findings; however, despite intrinsic
parameters to each NGS platform (e.g., read length, error rates,
cost per run, and turn-around time) we suspect that any of the
current NGS platforms will be effective in a genotypic test to
predict HIV-1 coreceptor usage.
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